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Abstract
The idea of utilizing immunotherapy for the treatment of cancers has been 
appealing to scientists and clinicians for over a several decades. Immunotherapy for 
cancers encompasses knowledge gained from a wide range of disciplines and has 
the potential to procure the ‘magic bullet’ for the treatment of cancer. Monoclonal 
antibody-based treatment of cancer has been recognized as one of the most suc-
cessful therapeutic strategies for both hematologic malignancies and solid tumours 
in the last 20 years. The discovery of hybridoma technology in late 1975 and the 
development of chimeric, humanized, and human antibodies have increased the 
availability and utility of immunotherapy for the treatment of cancer. Metastatic 
or recurrent cancer continues to be the bane of the urological oncologist. Despite 
recent improvements in therapeutic management and outcomes for clinically 
localized disease overall survival rate in patients with the majority of metastatic and 
recurrent genitourinary malignancies remains relatively unchanged. By targeting 
tumours through specific or associated antigens, it is possible to selectively elimi-
nate tumour cells and maintain an acceptable toxicity profile. Therapeutic antibod-
ies that target immune cells are also being developed with the goal of breaking local 
tolerance and stimulating the patient’s anti-tumor immune response. As with other 
treatment modalities, immunotherapy is far from perfect and requires additional 
study to optimize clinical response and overcome therapeutic resistance. Modern 
advances in the field of immunotherapy hold the promise of providing the clinical 
urologist/oncologist with new tools to fight urological cancer. However, the litera-
ture on monoclonal antibody-based immunotherapy with a particular emphasis 
on target antigens, monoclonal antibody design and potential applications in the 
field of urology is limited. Hence, the present chapter focuses on the applications of 
Immunotherapy using monoclonal antibodies for urologic oncology settings such 
as prostate, bladder, renal, testicular and penile with a hope to highlight its clinical 
efficacy and also its mechanisms of action in each of these cancer types.





Modern advances and a quantum leap in the field of cancer therapy has been prom-
ising to oncologists with new tools to fight many cancers. The immune system has mul-
tifunctional units referred to as antibodies, mostly polyclonal which facilitate humoral 
and cellular reactions to antigens [1]. However, it is possible to produce large quantities 
of an antibody from a single B-cell clone which are called as Monoclonal Antibodies 
(MAbs). Using these antibodies for therapeutic purposes is termed as Immunotherapy. 
Immunotherapy in recent times has been propitious across a number of cancer types. 
Stimulating results with MAbs directed towards both established and emerging targets 
indicate its potential key role as a therapeutic agent [2]. These are being tested in early- 
and late-stage clinical trials. In the last 35 years over 100 Monoclonal Antibodies have 
been considered potential as drugs and many have been approved. The usage of the 
monoclonal antibodies in cancer therapy requires the understanding of the biological 
role of various antigens involved in tumor growth [3]. In cancer patients’ immunity 
system is often altered. The purpose of immunotherapy with monoclonal antibodies 
is to interfere with synergic activity of immunosuppressive environment created by  
T cells, cytokines, interleukins and tumor growth factor [4]. In many cancer treatments, 
the monoclonal antibodies have been robust enough, however in some, combinatorial 
treatments including monoclonal antibodies, chemotherapy and vaccines have been 
successful thereby bringing together cancer immunologists and clinicians required 
for the management of cancer in the near future [5]. This chapter will focus on 
Immunotherapy using Monoclonal antibodies for many urologic oncology types such 
as prostate, renal, bladder, testicular and penile with a hope to highlight its clinical 
 utility and also its mechanisms of action in each of these cancer types.
2. Types of monoclonal antibodies and their mode of action
There are several ways by which the mAbs are made. They are as follows:
• Human: Theses are derived from the human source. Called as ‘umabs’
• Murine: These are derived from mouse. Called as ‘omabs’
• Humanized: Here the mouse proteins are attached to the human protein. 
Called as ‘zumabs’
• Chimeric: variable regions are from humans and constant regions are from 
mouse. Called as‘ximabs’
Following are the types of Monoclonal antibodies:
1. Naked monoclonal antibodies
a. These are the most common types of antibodies which are not attached to 
the radioactive material or any chemotherapy drugs. They act independently 
and have been extensively used to treat cancer. They attach themselves to 
antigens on cancer cells, or even non cancerous cells and other free-floating 
proteins. They can also act as immune checkpoint inhibitors [6]
b. E.g., alemtuzumab. This is used in the treatment of multiple sclerosis and 
leukemia (CLL).
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c. E.g., trastuzumab is a monoclonal antibody that acts against the HER2 
protein and used in the treatment of carcinoma of the breast in which this 
protein is expressed in larger amounts on the surface of the cancer cells. It 
thereby causes the inactivation of the protein by blocking it [7].
2. Conjugated monoclonal antibodies
As the name suggests these are in combination with the chemotherapy drugs 
or radioactive materials. These are referred to as tagged or labeled mAbs. 
They directly deliver the therapy to the target cells causing minimal damage 
to the normal cells surrounding them after precisely identifying them [8]. It 
then delivers the toxic substance where it is needed most. They can be of the 
following types;
a. Radiolabeled antibodies: These are conjugated with radiolabeled particles. 
An excellent example is Ibritumomab tiuxetan which works against the 
CD20 antigen found on B lymphocyte cells. It is made up of radioactive 
substance (Yttrium-90). The mAb works on the target cancer cells and then 
the radioactive materials target the destined cells and also the nearby cell. 
Radioimmunotherapy (RIT) is the name used for this type of treatment [9].
b. Chemolabeled antibodies: These mAbs have chemotherapy drugs attached 
to them. Eg: Ado-trastuzumab emtansine, an antibody that targets the HER2 
protein (breast cancer). It is covalently linked to the cytotoxic agent DM1
3. Bispecific monoclonal antibodies
These can attach to 2 different types of antigens at the same time, these have 
also been explored in cancer therapy and drug delivery. Example is blinatu-
momab, used in the treatment of acute lymphoblastic leukemia. It works by 
directing the body’s T-cells (part of the immune system) to target and bind 
with the CD19 protein on the surface of B-cell lymphoma cells [10].
3. Monoclonal antibodies and prostate cancer
Prostate cancer is one of the most common cancers with its incidence being high 
in Americans but lesser in the Asian population. It develops within the prostate 
gland that is responsible for the production of seminal fluid. Cancer therapy consid-
ered for prostate cancer includes radical prostatectomy, radiation therapy, chemo-
therapy, brachytherapy and hormone therapy [11]. The role of mAbs in Prostate 
cancer treatment has not been very successful. Several trials have been carried out 
to check for its efficacy, the details of which have been mentioned below.
Ipilimumab was the first immune checkpoint inhibitor which received FDA 
approval for the treatment of metastatic melanoma. It worked as the anti-cytotoxic 
T lymphocyte-associated protein 4 (CTLA-4). This stimulated its exploration for 
the treatment of prostate cancer. Use of this mAb in conjugation with radiation 
therapy did show antitumor activity in the form of decreasing PSA levels. This was 
a phase 1 trial. Hence, phase 3 clinical trials were conducted for further evaluation 
where subjects were randomized to ipilimumab after chemotherapy or radiation 
therapy. These trials did show progression free survival but missed its endpoint of 
overall survival [12].
Clinical trials on another mAb Nivolumab remains under investigation. In a first 
of its kind combination immunotherapy using monoclonal antibodies, Ipilimumab 
Monoclonal Antibodies
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plus nivolumab has been gaining responses as being reported in a phase 2 trial on 
metastatic castration resistant prostate cancer. Pembrolizumab is also an immune 
checkpoint inhibitor [13]. It has received approval from FDA for the treatment of 
prostate cancer. In these solid tumors, microsatellite instability (MSI) and mutations 
in mismatch repair genes (MMR) has been observed. Pembrolizumab is evaluated 
for in a patient after other effective treatments (such as sipuleucel-T, abiraterone, 
enzalutamide, docetaxel, cabazitaxel, radium-223, etc.) has been ruled out [14]. 
Combination therapies either with multiple immunotherapies or with immuno-
therapy and chemotherapy/RT, are currently being evaluated in prostate cancer. The 
optimal timing of immunotherapy in prostate cancer also remains unclear. Although 
much work remains to be done, the promise of prostate cancer immunotherapy 
remains unclear. There have been modern advances in the treatment of prostate can-
cer, however there is no curative treatment option once prostate becomes metastatic.
4. Monoclonal antibodies and renal cell carcinoma
Renal cell carcinoma is one of the urologic cancers that has lower incidence rates 
and poor prognosis. About 30% are diagnosed in their metastatic stage. It is a type of 
cancer that originates in the PCT. Therapy considered for this form of cancer include 
nephrectomy, radiation therapy, chemotherapy and embolization. The role of mAbs 
in Renal cell carcinoma is undertaken and studied in clinical trials treatment has 
not been very successful. Several trials have been carried out to check for its efficacy 
the details of which have been mentioned below as renal cell carcinoma (RCC) is a 
largely chemotherapy-resistant disease. It is immune responsive disease; therefore, 
checkpoint inhibitors can be considered as agents for the treatment of RCC [15].
The pivotal drug trial Checkmate 214 showed good objective responses in case of 
poor and intermediate risk patients in combination immunotherapy (Nivolumab/
Ipilimumab) vs. the tyrosine kinase inhibitor sunitinib and can be considered as 
a first line treatment in these subjects for RCC. However, for favorable high-risk 
patients, the single agent sunitinib showed more response rate. Survival rates were 
similar in both arms. In another clinical trial Keynote 426, Pembrolizumab (anti-
PD-1) plus axitinib, the responses were good and this led to its approval by leading 
to Food and Drug Administration (FDA) first line treatment. In another trial 
named, Javelin 101 Renal, avelumab (anti-PD-L1) plus axitinib vs. sunitinib the OS 
was not significantly different between the two arms [16].
In addition to this, there are many clinical trials that are underway for RCC 
(Table 1). Nivolumab was approved advanced clear-cell RCC by the FDA and is 
under investigation as pre- and postoperative therapy in mRCC. Combinatorial 
treatments with various drugs are also being studied in various clinical trials. 
Atezolizumab phase I trial involving 17 mRCC patients showed promising results 
as 7 had stable disease for more than 24 weeks. In another phase Ia study, of the 63 
patients with clear-cell RCC whose OS was 28.9 months. Pembrolizumab is currently 
being investigated in two randomized phase II trials of mRCC patients. It has been 
found to be acceptable for safe use [17]. Several trials evaluating pembrolizumab in 
combination with various agents are also undergoing. Avelumab showed an accept-
able usage when used in patients with advanced solid tumors and safety profile. Two 
ongoing trials are still being evaluated for avelumab in combination with axitinib 
Durvalumab. There are ongoing trials evaluating durvalumab in combination with 
other drugs, including tremelimumab for patients with advanced malignancies 
including RCC. Ipilimumab: Phase-II studies have been undergoing and the results 
are found to be partial response with adverse events being reported. In addition, 
Ipilimumab and nivolumab is being investigated and found to be favorable [18].
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5. Monoclonal antibodies and bladder cancer
Bladder cancer is one of the common cancers which develop in the tissues of the 
bladder. It is a type of Urolethial cancer. There are several methods which have been 
developed as a cancer therapy for bladder cancer and the most common being the, 
Bacillus Calmette-Guerin which has a very high success rate. The role of immuno-
therapy in Bladder cancer has been detailed in a number of case report and clinical 
trial studies [19]. The incidence of Bladder cancer is comparatively found to be 
higher in America when compared to other forms of malignancy.
Here are the various monoclonal antibodies that have been considered as a cancer 
therapy for the bladder cancer. 2016-Atezolizumab, was the first mAb to be approved 
by the FDA and also accepted by the European Association of Urology (EUA) as 
second-line therapy for patients with advanced Bladder Cancer. It is a PD-1/PD-L1 
checkpoint inhibitor It has been used for subjects even with metastatic or advanced 
bladder cancer. 2017-Avelumab was also approved by FDA for urothelial cancers. 
It acts against PD-L1. A phase Ib clinical trial had been carried out with metastatic 
urothelial cancer which showed inconvincing results. However in the phase II trial, 
avelumab exhibited a good antitumor response in patients with advanced urothelial 
cancer whose tumors progressed during or after platinum-based chemotherapy 
2017-Durvalumab has also received approval by FDA for the treatment of Bladder 
cancer. Studies in phases I and II patients have confirmed the effectiveness of dur-
valumab: It has shown responses in a number of clinical trial studies. It is a drug that 
acts against the PD-L1. 2017-Nivolumab is a FDA and EUA approved human mAb 
that acts against the PD-1. It was accepted on the basis of a single-arm phase trial for 
270 platinum pretreated patients. The result has been 20% response rate [20].
Nivolumab was also tested on advanced or metastatic Bladder cancer subjects. 
In this study many adverse events were reported. Unlike the above mentioned 
mAbs Targeted therapy Phase Population
Nivolumab Sunitinib
Pazopanib
I Advanced RCC, prior cytokine therapy 
allowed




Metastatic clear cell RCC, prior therapy 
allowed
Nivolumab Temsirolimus Ib/II Metastatic RCC, prior therapy allowed
Pembrolizumab Pazopanib I/II Untreated, advanced clear cell RCC
Pembrolizumab Axitinib Ib Untreated, advanced clear cell RCC
Pembrolizumab Bevacizumab Ib/II Metastatic clear cell RCC treated with 
failure of at least one prior therapy
Pembrolizumab Aflibercept I Metastatic RCC treated with at least one 
prior VEGF TKI
Avelumab Axitinib Ib Untreated, advanced clear cell RCC
Atezolizumab Bevacizumab III Untreated, advanced clear cell RCC
Avelumab Axitinib III Untreated, advanced clear cell RCC
Pembrolizumab Axitinib III Untreated, advanced clear cell RCC
RCC: Renal cell carcinoma; VEGF: Vascular Endothelial Growth Factor; TKI: Tyrosine kinase inhibitors.
Table 1. 
List of the Clinical trials that are underway for RCC.
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mAbs,PD-L1 overexpression among patients was not significant. In another phase 
II clinical trial with subjects also receiving platinum-based chemotherapy showed a 
two-month progression-free period. In patients with PD-L1 overexpression com-
pared to patients with low-expression, a difference in drug effects was observed. 
Many subjects did show adverse events [21].
Pembrolizumab has been showing positive responses in cases of advanced blad-
der cancer. It is a humanized monoclonal antibody used in the treatment of bladder 
cancer and is approved by the FDA and EAU. In a study conducted by on pembro-
lizumab by Bellmunt et al., it was observed that this mAb showed lower adverse 
events and longer survival by about 3 months which was significant when compared 
to chemotherapy drugs such as docetaxel and paclitaxel [22]. In a case report 
mentioning the treatment with pembrolizumab as reported by McDermott et al., it 
was observed that adverse events were not observed after 8 months and hence sug-
gested that pembrolizumab can be considered as a PD –I inhibitor [23]. In patients 
with DNA repair defects, pembrolizumab can also be considered for treatment. 
This drug not only reduced the risk of developing newer cancers but also prevented 
premalignant hyperplastic lesion. This shall be a rational therapy. Pembrolizumab 
is also shown better survival rates when compared to chemotherapy as mentioned 
farina and his colleagues.
A novel murine monoclonal antibody KMP1 has been studied by cheng and 
his colleagues [24]. The study was conducted both in vitro and in vivo settings It 
identified the CD44 epitope on bladder cancer cells and bound to it due to O-linked 
glycosylation and thereby exhibit antitumor potential in both settings. Future 
studies may be recommended to understand the exact glycolsylation mechanism 
also produce humanized forms and also conjugate types for better therapeutics. 
Enfortumab vedotin delivers toxic drugs to tumors. It is an antibody-drug conjugate 
that targets the Nectin-4 pathway, it has been approved for further study in case of 
bladder cancer. Immunotherapy has significantly reduced the risk of recurrence for 
bladder cancer while also increasing the percentage of patients who see a complete 
response post-surgery. Investigational bladder cancer immunotherapies also have 
the capacity change the outcomes positively for patients with this disease.
6. Monoclonal antibodies and testicular cancer
Testicular cancer is a disease of the male organ, testicles that produces the male 
hormones and sperms. Approximately 90% of testicular cancer start in the germ 
cells which make the sperm and are referred to as the Germ cell tumor (GCT). 
They are of two types: seminomas and non-seminomas. The testicular cancer 
are the solid tumors that can be treated by chemotherapy even in the metastatic 
condition. However, the role of immunotherapy is still under investigation. The 
incidence of Testicular cancer has observed an increasing trend in both America 
and Europe [25].
6.1 Testicular cancer
There are several trials that have been directed towards the Testicular cancer. 
Several of these trials are against the Immune check point inhibitors. Many 
case studies have reported immune checkpoint inhibition efficacy in refractory 
GCTs. However, the mechanism by which this occurs is not clear. Trials have been 
conducted with mAbs, nivolumab or pembrolizumab (both anti-PD-1 agents) 
on subjects with refractory GCT. The results are very inconvincing on a phase 
II trial of Adra et al. [26] who administered pembrolizumab to 10 refractory 
7
Therapeutic Applications of Monoclonal Antibodies in Urologic-Oncology Management…
DOI: http://dx.doi.org/10.5772/intechopen.96911
GCT patients. Despite of the PD-L1 status there were no responses and hence 
this led to the termination of the trial. Although three of seven patients with 
refractory germ cell tumors treated with nivolumab or pembrolizumab did show 
response, there was partial remission. Some case reports did mention about the 
rapid progression of the disease with pembrolizumab on single dose and some 
40% response with single dose of nivolumab. In a case study reported by Chi 
and Schweizer, treatment response to nivolumab was observed hence, use of 
single checkpoint inhibitors have been unstable in nature [27]. No responses 
were observed by nadal et al. for a case report on a study conducted using 
Nibolumabwith cabozantini and bipilimumab [28]. Due to inefficacy of single 
agent durvalumab, the monotherapy arm was closed for a study conducted by 
Raggi et al. [29] Hence the results of immune checkpoint inhibitor monotherapy 
studies are disappointing and hence need more evaluation in many more clinical 
trials that shall be planned for future.
7. Monoclonal antibodies and penile cancer
Penile Cancer is a disease in which a tumor growth occurs in the tissues of the 
Penis. Although the localized penile cancer can be treated by penectomy, the meta-
static forms need better strategies to deal with such as the standard Chemotherapy 
or the novel Immunotherapy. About 95% of the penile cancers are squamous cell 
carcinomas and other forms include the sarcoma, melanomas and the basal cell 
carcinoma. Most of the penile cancer is caused by HPV (human papilloma virus) 
infection. Although the incidence of Penile cancer is only about 1 in every 1,00,000 
individuals I America and Europe, several Immunotherapy drug trials are underway 
to strategize its importance.
Epidermal growth factor receptor is usually overly expressed in Penile squamous 
cell carcinoma. EGFR amplification has been observed and thereby reported in 
a number of studies on primary penile squamous cell carcinoma. This amplifica-
tion has been observed with poor prognosis in patients with penile squamous cell 
carcinoma and increased risk of recurrence. Considering this aspect, it has been 
chosen for treatment of systemic penile cancer. Immunotherapy towards EGFR tar-
get, includes monoclonal antibodies cetuximab and panitumumab [28]. In a study 
considering cetuximab either alone or with cisplatin, there was partial response. In 
another study considering cetuximab, panitumumab, and nimotuzumab about 50% 
of the patients showed response to treatment. However, this was a second line of 
treatment.
In addition to anti-EGFR therapy, immune checkpoint inhibitor drug trials 
of avelumab and pembrolizumab are under progress. These drugs are evaluating 
the role of PD- L1 and PD-1 inhibition with the above mentioned mAbs respec-
tively, exclusively in penile carcinoma. The combination of PD-1 and cytotoxic 
T lymphocyte protein 4 (CTLA4) blockade might improve antitumour activity 
across multiple malignancies, including PSCC. However, the majority of the 
trials with patients suffering from penile carcinoma are basket trials that include 
because incidence of penile squamous cell carcinoma is very low [30]. In addition, 
Cetuximab, a chimeric monoclonal antibody is an epidermal growth factor recep-
tor (EGFR) inhibitor and has still not received FDA approval for the treatment of 
penile cancer. Phase I trials of Nivolumab are also underway which is a conjunc-
tion of chemotherapy and lymphokine working against the HPV. As the frequency 
of this disease is very low, it has been difficult to conduct many trials. However, 
continual progress in the area of Immunotherapy with fewer trials has still been 




Immune status modification as strategy of cancer therapy does hold a significant 
place. Although, the conventional cancer treatments such as surgery, chemotherapy, 
and radiotherapy are still being referred to as the prominent ones, for some cancer 
types, immunotherapies are considered as first-line of treatment. One of the most 
important discoveries in the last several years in immunotherapy has been the develop-
ment of immune checkpoint inhibitor, monoclonal antibodies that promote antitumor 
activity. T cells are a form of lymphocyte which are produced within the thymus 
and performs a crucial function in stimulating body’s immune reaction to combat 
most cancers. They apprehend the overseas particles (antigens) with the aid of using 
particularly variable T cell receptor. Unlike antibody, the TCR cannot bind antigen 
and as a substitute it wishes to have peptides of the antigen proven to it with the aid of 
using an antigen presenting cell (APC). The molecules at the APC that gift the antigen 
are called as major histocompatibility complexes (MHC). Many stimulatory alerts 
also are wanted at this time. B7 is a form of peripheral membrane protein observed 
on activated antigen-providing cells (APC). This B7 on an APC can bind to cytotoxic 
T-lymphocyte-related antigen 4 (CTLA-4) developing an inhibitory sign and TCR 
activation. Once the activated T-cell receptor is within the tumor surroundings it is able 
to apprehend the antigen supplied with the aid of APC within the tumor. At this time, 
the programmed cell death protein 1 (PD-1) receptor also sends an inhibitory signal to 
the T-cell when the receptor binds to programmed cell death 1 ligand 1 (PD-L1), that’s 
regularly expressed on tumor cells. Monoclonal antibodies act by inhibiting the bind-
ing PD-1 to PD-L1 and thereby boost body’s immune response against the tumor cells.
Checkpoint inhibitors specifically goal PD-1/PD-L1) and CTLA4 Immune 
checkpoint efficacy is stricken by diverse factors, among which are tumor genom-
ics, host germline genetics, PD-L1 levels, and intestine microbiome. Generally, in 
tumors, mutated or incorrectly expressed proteins are processed through the immu-
noproteasome into peptides which can be commonly loaded onto MHC molecules, 
which similarly now no longer usually are capable of eliciting CD8+ T cell reaction. 
This may also cause producing MHC-supplied immunogenic neoepitopes. It turned 
into proven, that after the intratumor heterogeneity rises, neoantigen-expressing 
clones emerge as greater homogenous with the differential expression of PD-L1.
There are number of FDA approved monoclonal antibodies, that are considered 
for the treatment of Urology oncology. These have been detailed in the Table 1 
and include FDA-approved PD-1 inhibitors such as nivolumab, pembrolizumab, 
cemiplimab, and FDA-approved PD-L1 such as atezolizumab, avelumab, and 
durvalumab. But all the open literatures do believe that combinatorial strategies 
with immune checkpoint therapies may provide a better survival benefit which 
have been demonstrated in various clinical trials. These can be in combination 
with radiation therapy, tyrosine kinase inhibitors and also many chemotherapeutic 
drugs. However, the response to immunotherapy with monoclonal antibodies varies 
subjectively and hence research into PD-L1 expression, gene signature expression, 
messenger RNA subtype, mutational and neoantigen load is essential to determine 
the varying response to monoclonal antibody immunotherapy. Although older 
modalities of treatment for cancer, has been extensively exploited, array of new 
drugs that offer hope of not only prolonging life but also curing significantly more 
patients in the future bring a ray of hope to the scientific world.
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